JPWO2023034761A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023034761A5 JPWO2023034761A5 JP2024513347A JP2024513347A JPWO2023034761A5 JP WO2023034761 A5 JPWO2023034761 A5 JP WO2023034761A5 JP 2024513347 A JP2024513347 A JP 2024513347A JP 2024513347 A JP2024513347 A JP 2024513347A JP WO2023034761 A5 JPWO2023034761 A5 JP WO2023034761A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- adenine
- complement
- creb3l3
- position corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239304P | 2021-08-31 | 2021-08-31 | |
| US63/239,304 | 2021-08-31 | ||
| PCT/US2022/075610 WO2023034761A1 (en) | 2021-08-31 | 2022-08-29 | Treatment of liver diseases with camp responsive element binding protein 3 like 3 (creb3l3) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531507A JP2024531507A (ja) | 2024-08-29 |
| JPWO2023034761A5 true JPWO2023034761A5 (https=) | 2025-06-09 |
| JP2024531507A5 JP2024531507A5 (https=) | 2025-06-09 |
Family
ID=83457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513347A Pending JP2024531507A (ja) | 2021-08-31 | 2022-08-29 | Ｃａｍｐ応答性エレメント結合タンパク質３様３（ｃｒｅｂ３ｌ３）阻害剤による肝疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230160012A1 (https=) |
| EP (1) | EP4395888A1 (https=) |
| JP (1) | JP2024531507A (https=) |
| KR (1) | KR20240058125A (https=) |
| CN (1) | CN118265529A (https=) |
| AU (1) | AU2022339755A1 (https=) |
| CA (1) | CA3228930A1 (https=) |
| IL (1) | IL310697A (https=) |
| WO (1) | WO2023034761A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR067446A1 (es) * | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
| WO2012051301A1 (en) * | 2010-10-12 | 2012-04-19 | President And Fellows Of Harvard College | Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism |
| EP3220911B1 (en) * | 2014-11-17 | 2018-11-07 | Universitá Degli Studi Salerno | Levosimendan for use as a liver protector |
-
2022
- 2022-08-29 JP JP2024513347A patent/JP2024531507A/ja active Pending
- 2022-08-29 US US17/823,057 patent/US20230160012A1/en active Pending
- 2022-08-29 CA CA3228930A patent/CA3228930A1/en active Pending
- 2022-08-29 IL IL310697A patent/IL310697A/en unknown
- 2022-08-29 AU AU2022339755A patent/AU2022339755A1/en active Pending
- 2022-08-29 CN CN202280067542.3A patent/CN118265529A/zh active Pending
- 2022-08-29 KR KR1020247010325A patent/KR20240058125A/ko active Pending
- 2022-08-29 EP EP22777885.9A patent/EP4395888A1/en active Pending
- 2022-08-29 WO PCT/US2022/075610 patent/WO2023034761A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7248760B2 (ja) | 肝特異的核酸調節要素ならびにその方法および用途 | |
| Chiba et al. | Uteroglobin-related protein 1 expression suppresses allergic airway inflammation in mice | |
| JP2019500345A (ja) | 肝臓病の処置のための組成物および方法 | |
| Nohira et al. | Identification of an alternative splicing transcript for the resistin gene and distribution of its mRNA in human tissue | |
| CN118252938B (zh) | 抑制或敲除Jun基因表达的试剂用于治疗射血分数保留的心衰的用途 | |
| CN108004310B (zh) | 肾素(原)受体(p)rr基因及其抑制剂的应用 | |
| AU2021335200A9 (en) | Treatment of sepsis with pcsk9 and ldlr modulators | |
| JPWO2023034761A5 (https=) | ||
| US20250188473A1 (en) | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | |
| WO2024216654A1 (zh) | 一种载脂蛋白h在预防和/或治疗脂肪肝及相关疾病药物中的应用 | |
| CN110327363A (zh) | 基于hsa-miR-320a的防治糖尿病的药物及其筛选方法和制备方法 | |
| KR101607629B1 (ko) | miRNA를 이용한 C형 간염 바이러스 감염 질환의 예방 또는 치료 | |
| JP7575396B2 (ja) | 溶質キャリアファミリー３９メンバー５（ｓｌｃ３９ａ５）阻害剤を用いた高血糖の処置 | |
| Ghazalah et al. | Genetic study of I kappa B alpha gene promoter polymorphism associated with hepatitis C virus in Egyptian patients | |
| KR20210110623A (ko) | 아라키도네이트15-리폭시게나제 (alox15) 억제제를 사용하는 호흡기 장애의 치료 | |
| CN118272371B (zh) | 靶向plin2基因的小干扰核酸、短反义寡核苷酸及其用途 | |
| CN100494400C (zh) | 电压调控钠通道7型α亚单位基因与原发性高血压的相关性 | |
| KR20240067064A (ko) | 레티쿨로칼빈-3[rcn3] 변이체 및 인터류킨-4 수용체 알파[il4r] 길항제를 이용한 천식의 치료 | |
| CN118265529A (zh) | 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗 | |
| RU2024117724A (ru) | Лечение болезней почек ингибиторами ангиопоэтин-подобного белка 3 (angptl3) | |
| JP2001149076A (ja) | 慢性ｃ型肝炎患者におけるインターフェロン治療の有効性の判定方法 | |
| JPWO2023064850A5 (https=) | ||
| CN105251022A (zh) | 叉头样转录因子foxa2在制备治疗慢性肝病药物中的应用 | |
| CN121816419A (zh) | 用卵泡素相互作用蛋白1 (fnip1)抑制剂和/或卵泡素(flcn)抑制剂治疗肝病或代谢病症 | |
| CN118159655A (zh) | 小rna及其在高血脂治疗中的用途 |